In a report released on February 7, Heiko Ihle from H.C. Wainwright reiterated a Buy rating on UR-Energy (URG – Research Report), with a price ...

H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

H.C. Wainwright raised the firm’s price target on NextTrip (NTRP) to $5 from $2.50 and keeps a Neutral rating on the shares after the company ...

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a report released on ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. (Operator Instructions) I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of ...

LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical ...

Langan reaffirmed the company’s five-year capital allocation strategy, aiming for $400 million in revenue and $75 million in free cash flow by FY29. The plan focuses on growing free cash flow per ...